Drug intelligence / Profile preview

KIVU-305

Development stage: Phase 1
Lead developer: Kivu Bioscience
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KIVU-305 is an antibody-drug conjugate (ADC) being developed by Kivu Bioscience for the treatment of neoplasms, specifically solid tumors. The drug leverages advanced proprietary ADC technologies, including Synaffix’s GlycoConnect™ site-specific conjugation platform, to create highly stable and homogenous ADCs with optimized linker and payload combinations. This approach aims to maximize therapeutic efficacy while minimizing off-tumor toxicity. The payload used in KIVU-305 is a topoisomerase I inhibitor, designed for high potency, bystander killing capability, and resistance to drug efflux transporters. As of March 2025, KIVU-305 is in preclinical development[1][2][3][4].

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on KIVU-305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIVU-305.

Explore the full profile